Pharming Group's Participation in Noteworthy Investor Conference
Leiden, the Netherlands: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is excited to announce its active participation in a prominent investor conference this month. This engagement reflects Pharming's commitment to keeping stakeholders informed about their advancements and initiatives.
Details of the Canaccord Genuity Conference
Pharming's management team will showcase their insights at the Canaccord Genuity 45th Annual Growth Conference. This event is scheduled to take place in Boston, USA, where Chief Executive Officer Fabrice Chouraqui is set to present on Tuesday during a key time slot. Attendees can expect in-depth discussions about Pharming's innovative approaches and developments in the biopharmaceutical field.
Conference Presentation Details
On August 12, 2025, at 12:00 PM EDT/6:00 PM CEST, Fabrice Chouraqui will deliver a presentation that dives deep into Pharming's strategic vision and operational successes. This is an excellent opportunity for investors to gain valuable insights directly from the company’s leadership.
Enhancing Investor Engagement and Relationships
Pharming encourages interested parties to reach out for more details regarding the conference. The Investor Relations team is readily available for one-on-one meetings with stakeholders, ensuring a thorough exchange of information regarding Pharming's future direction and current projects. You can contact the team via email for scheduling inquiries.
Pharming’s Commitment to Innovation
Pharming Group N.V. is at the forefront of transforming lives through innovative biopharmaceutical solutions. By spearheading the development of both small molecules and biologics, they are dedicated to addressing the needs of patients battling rare and serious health conditions. With a strong presence in over 30 global markets, Pharming is committed not only to commercializing emerging therapies but also to enhancing the overall quality of life for patients.
Contact Information for Further Inquiry
For additional public information about Pharming, stakeholders can reach out to the company’s headquarters in Leiden. Michael Levitan, the Vice President of Investor Relations & Corporate Communications, is available to discuss any inquiries. Engaging with stakeholders remains a top priority for Pharming, and they value communication as a means to enrich partnerships.
Global Reach and Impact
With operations spanning North America, Europe, and Asia-Pacific, Pharming is strategically positioned to influence the global biopharmaceutical landscape. Their advanced research and commitment to bringing forth effective treatments play a crucial role in the healthcare ecosystem.
Frequently Asked Questions
What major event is Pharming participating in this month?
Pharming will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston.
When will the presentation take place?
The presentation is scheduled for August 12, 2025, at 12:00 PM EDT/6:00 PM CEST.
Who can attend the conference?
Investors and analysts are encouraged to attend the conference to learn more about Pharming's initiatives.
How can investors contact Pharming’s management?
Investors can reach out to Pharming’s Investor Relations team via email to schedule meetings and inquiries.
What is Pharming's focus as a biopharmaceutical company?
Pharming is dedicated to developing innovative medicines for patients with rare and serious diseases.
